Sex: U
Vaccine: COVID19
Symptoms: Blood creatine, Blood thyroid stimulating hormone, COVID-19, Drug ineffective, X-ray
Clinical narrative: I did get covid; I did get covid; This is a spontaneous report received from a Consumer or other non HCP from product quality group.  A patient (age and gender not provided) received BNT162b2 omi xbb.1.5 (BNT162B2 OMI XBB.1.5), on 22Sep2023 as dose 1, single (Lot number: HG4628) for covid-19 immunisation. The patient's relevant medical history included: "CKD", start date: 1969 (ongoing), notes: Illness/AE: CKD, Onset date: 1969, Stop date: ongoing checked, Pertinent Details: Dialysis 1996-1998, transplant 1998; "Aortic stenosis", start date: 2008 (ongoing), notes: Illness/AE: Aortic stenosis, Onset date: 2008, Stop date: ongoing checked, Pertinent Details: Bovine replacement 2011 new one needed soon; "hypothyroidism", start date: 1985 (ongoing), notes: Illness/AE: hypothyroidism, Onset date: 1985, Stop date: ongoing checked, Pertinent Details: controlled with levothyroxine; "osteoarthritis", start date: 1970 (ongoing), notes: Illness/AE: osteoarthritis, Onset date: 1970, Stop date: 2018 ongoing checked, Pertinent Details: 2 TKR 2017 L 2018 R. The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (DOSE 1, SINGLE, Dose: 1st, Date / Time: , Date: 29Jan2021, Time: 17.00, Site and Route of injection:, Anatomical Site of injection: Arm, Route of administration: Intramuscular~, Batch/Lot number: EL9261), administration date: 29Jan2021, for Covid-19 Immunization; BNT162b2 (DOSE 2, SINGLE, Dose: 2nd, Date / Time: , Date: 18Feb2021, Time: 7.30, Site and Route of injection:, Anatomical Site of injection: Arm, Route of administration: Intramuscular~, Batch/Lot number: EM9809), administration date: 18Feb2021, for Covid-19 Immunization; BNT162b2 (DOSE 3 (BOOSTER), SINGLE, Dose: 3rd, Date / Time: , Date: 16Aug2021, Time: 11.00, Site and Route of injection:, Anatomical Site of injection: Arm, Route of administration: Intramuscular~, Batch/Lot number: FC3181), administration date: 16Aug2021, for COVID-19 immunization; BNT162b2 (DOSE 5 (BOOSTER), SINGLE, 04Jun2022 FM7553 arm), administration date: 04Jun2022, for COVID-19 immunization; BNT162b2 (DOSE 6 (BOOSTER), SINGLE, 19Sep2022 GH9693), administration date: 19Sep2022, for COVID-19 immunization; BNT162b2 (DOSE 7 (BOOSTER), SINGLE, 17May2023 GL1990), administration date: 17May2023, for COVID-19 immunization; tdap (1, Vaccine Name: TDap~, Manufacturer: (Withheld), Batch/Lot#: Fn74z 0000267917~, Route: Intramuscular, Anatomical Site of Injection: arm~, No. of Previous Doses: 1, Date: 14Jan2021), administration date: 14Jan2021, for Immunization; flu (2, Vaccine Name: Flu, Manufacturer: withheld, Batch/Lot#: 370267, Route: Intramuscular , Anatomical Site of Injection: left delt, No. of Previous Doses: Every year since 1973, Date: 11Sep2023), administration date: 11Sep2023, for Immunization; Bnt162b2 (DOSE 4 (BOOSTER), SINGLE, Dose: 4th, Date / Time: , Date: 22Jan2021, Time: 11.00, Site and Route of injection:, Anatomical Site of injection: Arm, Route of administration: Intramuscular~, Batch/Lot number: FH8020), for COVID-19 immunization. The following information was reported: DRUG INEFFECTIVE (hospitalization, medically significant), COVID-19 (hospitalization, medically significant) all with onset 16Dec2023, outcome "unknown" and all described as "I did get covid". The patient underwent the following laboratory tests and procedures: Blood creatine: High creatinine; Blood thyroid stimulating hormone: Low TSA; X-ray: osteoarthrtis. Therapeutic measures were taken (given Remdesivir at the Hospital) as a result of drug ineffective, covid-19.